Welcome to the international HTA database

Showing [21846 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021	Agency for Healthcare Research and Quality (AHRQ)	Integrated and comprehensive pain management programs: effectiveness and harms
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Allocation of scarce resources in critical care units in a pandemic]
2021	Agency for Care Effectiveness (ACE)	Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021	Agency for Healthcare Research and Quality (AHRQ)	Integrating palliative care in ambulatory care of noncancer serious chronic illness: a mixed-methods review
2021	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Review of the evidence on the impact of school closures through the evolution of the COVID-19 pandemic]
2021	NIHR Health Technology Assessment programme	Cognitive–behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[SGLT2 inhibitors in heart failure]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (malignant pleural mesothelioma) - Addendum to Commission A21-89]
2021	NIHR Health Technology Assessment programme	Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ambulatory oxygen therapy in COVID-19]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2021	Agency for Healthcare Research and Quality (AHRQ)	Interventional treatments for acute and chronic pain: systematic review
2021	NIHR Health Services and Delivery Research programme	Respite care and short breaks for young adults aged 18–40 with complex health-care needs: mixed-methods systematic review and conceptual framework development
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V]
2021	Norwegian Institute of Public Health (NIPH)	Surgery for carpal tunnel syndrome: a health technology assessment
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eye controlled speech generating device]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Risdiplam in spinal muscular atrophy]
2021	Agency for Care Effectiveness (ACE)	Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tirbanibulin (actinic keratosis) - Benefit assessment according to §35a Social Code Book V]
2021	Agency for Healthcare Research and Quality (AHRQ)	Interventions to decrease hospital length of stay
2021	Norwegian Institute of Public Health (NIPH)	Evaluation of tests for FLT3 mutations in acute myeloid leukaemia (AML)
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stem cell therapy: clinical applications]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021	NIHR Health Technology Assessment programme	DISC: Dupuytren's Interventions Surgery vs. Collagenase. A pragmatic multi-centre randomised controlled non-inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren's contracture in adult patients
2021	Norwegian Institute of Public Health (NIPH)	Subacromial decompression surgery for impingement syndrome: rapid health technology assessment
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Non-invasive respiratory support in Covid-19 patients]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Migalastat (Fabry disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Brolucizumab in neovascular age-related macular degeneration]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[COVID-19: follow-up after an acute episode]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Microperimetry in retinopathies]
2021	Agency for Healthcare Research and Quality (AHRQ)	Malnutrition in hospitalized adults
2021	NIHR Health Technology Assessment programme	Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cardiopulmonary resuscitation in COVID-19 patients]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for updating the DMP "Heart failure"]
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical Practice Guideline on adult's palliative care]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Patisiran and inotersen in hereditary transthyretin-mediated amyloidosis]
2021	Agency for Healthcare Research and Quality (AHRQ)	Management of high-need, high-cost patients: a "best fit" framework synthesis, realist review, and systematic review
2021	NIHR Health Technology Assessment programme	Impact of multiparametric MRI on staging and management of patients with suspected or confirmed ovarian cancer Short title: MR in Ovarian Cancer (MROC study)
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Whole-exome sequencing in patients with neurological disorders]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95]
2021	NIHR Health Services and Delivery Research programme	Pay More Attention: a national mixed methods study to identify the barriers and facilitators to ensuring equal access to high quality hospital care and services for children and young people with learning disability and their families
2021	NIHR Health Technology Assessment programme	UK Cohort study to Investigate the prevention of Parastomal Hernia (CIPHER)
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transcatheter aortic valve implantation in severe aortic stenosis]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vericiguat (cardiac failure) - Benefit assessment according to §35a Social Code Book V]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: initiating pharmacological treatment for clearing an occluded central venous access device (CVAD)]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Swallowable gastric balloon in obesity]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Whole exome sequencing in patients with intellectual disability and/or autism spectrum disorder]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Extracranial stereotactic body radiotherapy in oligometastasis]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tafasitamab (diffuse large cell B-cell lymphoma, combination with lenalidomide) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
2021	Belgian Health Care Knowledge Centre (KCE)	Do innovative medicines against cancer always have a real added value?
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Whole exome sequencing in epileptic encephalopathies]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Odevixibat (cholestasis [from 6 months]) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Baricitinib in COVID-19 patients]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Edaravone in patients with amyotrophic lateral sclerosis]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97]
2021	Agency for Healthcare Research and Quality (AHRQ)	Maternal, fetal, and child outcomes of mental health treatments in women: a systematic review of perinatal pharmacologic interventions
2021	Norwegian Institute of Public Health (NIPH)	[Intravenous immunoglobulin treatment in children with PANS/PANDAS conditions]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Hemlibra (emicizumab) – Hemophilia A without inhibitor (re evaluation)]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Second addendum to Commission A20-61]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: clinical utility of the different Western blot antigen profiles in the context of disseminated Lyme disease]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: chronic” Lyme disease: current state of knowledge and overview of the different perspectives]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence on orphan drugs]
2021	NIHR Health Technology Assessment programme	Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study
2021	Scottish Medicines Consortium (SMC)	Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021	NIHR Health Technology Assessment programme	A multicentre randomised controlled trial of induced endometrial trauma in women undergoing first time In Vitro Fertilisation (IVF)
2021	Scottish Medicines Consortium (SMC)	Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021	NIHR Health Technology Assessment programme	Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study
2021	Scottish Medicines Consortium (SMC)	Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibalizumab (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	Facilitating the return to work of NHS staff with common mental health disorders: a feasibility study
2021	Scottish Medicines Consortium (SMC)	Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021	Canary Health Service	[Real-time continuous glucose monitoring device for gestational diabetes]
2021	NIHR Health Technology Assessment programme	QUIDS Quantitative fibronectin to help decision-making in women with symptoms of preterm labour
2021	NIHR Health Technology Assessment programme	The Invasive Dentistry Endocarditis Association Study: the IDEA Study
2021	Scottish Medicines Consortium (SMC)	Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021	Canary Health Service	[Monitoring study: "The sensor glucose monitoring system (flash-type) for type 1 diabetes mellitus in childhood and adolescence]
2021	NIHR Health Technology Assessment programme	Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT
2021	NIHR Health Technology Assessment programme	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT
2021	Scottish Medicines Consortium (SMC)	Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on dementia: Structural imaging]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: validation of the management framework for a nonspecific human immunoglobulin shortage]
2021	Canary Health Service	[Effectiveness, safety, and cost-effectiveness of devices for peripheral venous catheterization: needleless connectors, passive disinfection caps and prefilled saline syringes]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: standards for the management of acute ST-segment elevation myocardial infarction (STEMI) in Québec (update of April 2021)]
2021	Canary Health Service	[Decisional flowchart for patient involvement in health technology assessments]
2021	Agency for Healthcare Research and Quality (AHRQ)	Physical activity and the health of wheelchair users: a systematic review in multiple sclerosis, cerebral palsy, and spinal cord injury
2021	Canary Health Service	[Scalp cooling devices for the prevention of chemotherapy-induced alopecia]
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Internet-based psychological treatment for anxiety and depression]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]
2021	Scottish Health Technologies Group (SHTG)	NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling